/PHVS
PHVS Stock - Pharvaris N.V.
Healthcare|BiotechnologyNASDAQ
$25.59+6.54%
+$1.57 (+6.54%) • Dec 19
88
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+78.2%upside
Target: $45.60
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PHVS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$25.33 – $25.85
TARGET (TP)$45.60
STOP LOSS$23.54
RISK/REWARD1:9.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-2.80
52W High$29.80
52W Low$11.51
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-8,436.951 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-145,688,167 | $-96,913,620 | $-86,714,608 | $-54,138,626 | $-28,506,875 |
| Net Income | $-134,221,000 | $-100,875,068 | $-76,332,557 | $-42,730,779 | $-29,623,037 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.48 | $-2.63 | $-2.27 | $-1.41 | $-0.85 |
Company Overview
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
67%
Hold / Neutral
2
22%
Sell / Underperform
1
11%
Analyst Consensus🟡 Mixed
6 Bullish3 Neutral/Bearish
Price Targets
$27
Average Target
↑ 6.2% Upside
Now
$10
Low
$27
Average
$60
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 15th 2025 | H.C. Wainwright | Initiation | Buy | $60 |
| October 9th 2025 | BofA Securities | Upgrade | Neutral | $27 |
| June 11th 2025 | Guggenheim | Initiation | Buy | $32 |
| April 29th 2025 | Cantor Fitzgerald | Initiation | Overweight | $28 |
| September 25th 2023 | Wedbush | Initiation | Outperform | $27 |
| August 15th 2023 | Morgan Stanley | Upgrade | Overweight | $34← $10 |
| October 5th 2022 | Bryan Garnier | Initiation | Buy | $16 |
| September 13th 2022 | JMP Securities | Resumed | Mkt Outperform | $18← $34 |
| August 23rd 2022 | Morgan Stanley | Downgrade | Equal Weight | $10← $40 |
| August 22nd 2022 | BofA Securities | Downgrade | Underperform | $13← $26 |
| May 25th 2022 | JMP Securities | Initiation | Mkt Outperform | $34 |
Earnings History & Surprises
PHVSBeat Rate
44%
Last 16 quarters
Avg Surprise
-11.6%
EPS vs Estimate
Beats / Misses
7/8
1 met exactly
Latest EPS
$-0.70
Q4 2025
EPS Surprise History
Q2 24
-41.4%
$-0.82vs$-0.58
Q2 24
0.0%
$-0.56vs$-0.56
Q3 24
-3.5%
$-0.59vs$-0.57
Q4 24
-28.8%
$-0.85vs$-0.66
Q1 25
No data
Q2 25
-11.2%
$-0.89vs$-0.80
Q3 25
-8.0%
$-0.94vs$-0.87
Q4 25
+10.3%
$-0.70vs$-0.78
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 6, 2026 | $-0.71 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.78 | $-0.70 | +10.3% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.87 | $-0.94 | -8.0% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.80 | $-0.89 | -11.2% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | — | $-0.93 | — | — |
Q4 2024 | Nov 13, 2024 | $-0.66 | $-0.85 | -28.8% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.57 | $-0.59 | -3.5% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.56 | $-0.56 | 0.0% | = MET |
Q2 2024 | Apr 3, 2024 | $-0.58 | $-0.82 | -41.4% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.67 | $-0.63 | +6.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.71 | $-0.69 | +2.8% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.81 | $-0.72 | +11.1% | ✓ BEAT |
Q2 2023 | Apr 5, 2023 | — | $-0.73 | — | — |
Q4 2022 | Dec 8, 2022 | $-0.64 | $-0.25 | +60.9% | ✓ BEAT |
Q3 2022 | Jul 1, 2022 | — | $-0.39 | — | — |
Q2 2022 | May 11, 2022 | $-0.49 | $-0.54 | -10.2% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-0.74 | $-0.47 | +36.5% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.49 | $-0.46 | +6.1% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | $-0.51 | $-1.13 | -121.6% | ✗ MISS |
Q2 2021 | May 26, 2021 | $-0.34 | $-0.66 | -94.1% | ✗ MISS |
Latest News
Oppenheimer Maintains Outperform on Pharvaris, Raises Price Target to $50
📈 PositiveBenzinga•Dec 4, 2025, 06:09 PM
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $39
📈 PositiveBenzinga•Dec 4, 2025, 01:54 PM
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $41
📈 PositiveBenzinga•Dec 4, 2025, 01:04 PM
B of A Securities Maintains Neutral on Pharvaris, Raises Price Target to $30
➖ NeutralBenzinga•Dec 4, 2025, 12:13 PM
HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target
📈 PositiveBenzinga•Dec 3, 2025, 07:13 PM
Pharvaris shares are trading higher after the company announced RAPIDe-3 data confirming the potential of deucrictibant's differentiated profile for the on-demand treatment of HAE attacks.
📈 PositiveBenzinga•Dec 3, 2025, 01:57 PM
Pharvaris' RAPIDe-3 Phase 3 Trial Of Deucrictibant For The On-demand Treatment Of Hereditary Angioedema Attacks Met The Primary Endpoint Of Median Time To Onset Of Symptom Relief, Achieved In 1.28 Hours, Significantly Faster Than Placebo
📈 PositiveBenzinga•Dec 3, 2025, 11:56 AM
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $37
📈 PositiveBenzinga•Nov 14, 2025, 04:51 PM
Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $30
📈 PositiveBenzinga•Nov 13, 2025, 02:15 PM
HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 12:32 PM
Pharvaris Q3 EPS $(0.64) Beats $(0.78) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:06 PM
Pharvaris Presents Open-Label Prophylaxis Data Supporting Long-Term Safety Profile, Sustained Benefits Of Deucrictibant, And Clinical Validation Data Of Kinin Biomarker Assay, At ACAAI 2025
📈 PositiveBenzinga•Nov 10, 2025, 11:53 AM
HC Wainwright & Co. Initiates Coverage On Pharvaris with Buy Rating, Announces Price Target of $60
📈 PositiveBenzinga•Oct 15, 2025, 10:18 AM
B of A Securities Upgrades Pharvaris to Neutral, Raises Price Target to $27
📈 PositiveBenzinga•Oct 9, 2025, 10:55 AM
Pharvaris prices $175M securities offering
📈 PositiveSeeking Alpha•Jul 23, 2025, 05:20 AM
Pharvaris announces public offering of ordinary shares
➖ NeutralSeeking Alpha•Jul 22, 2025, 08:21 PM
Frequently Asked Questions about PHVS
What is PHVS's current stock price?
Pharvaris N.V. (PHVS) is currently trading at $25.59 per share. The stock has moved +6.54% today.
What is the analyst price target for PHVS?
The average analyst price target for PHVS is $45.60, based on 1 analyst.
What sector is Pharvaris N.V. in?
Pharvaris N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PHVS's market cap?
Pharvaris N.V. has a market capitalization of $1.66 billion, making it a small-cap company.
Does PHVS pay dividends?
No, Pharvaris N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDX
Ardelyx, Inc.
$5.68
Mkt Cap: $1.4B
BCRX
BioCryst Pharmaceuticals, Inc.
$7.41
Mkt Cap: $1.6B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to PHVS for comparison